Bromperidolo decanoato del disturbo schizofrenico in fase residua

Translated title of the contribution: Bromperidol decanoate in the residual phase of schizophrenia

E. Smeraldi, C. Cocconcelli, L. Canova, C. Faravelli, F. P. Marchetti, G. Mariani, V. Rapisarda

Research output: Contribution to journalArticle

Abstract

We assessed the safety and therapeutic efficacy of bromperidol decanoate in a six-month open trial on 21 patients (13 males and 8 females), mean age 41.3 years, who were no longer in the acute phase and were being treated as outpatients. The recommended initial dosage was 150 mg bromperidol (one 3 ml ampoule), and this did not in fact have to be increased during the trial. The scores for psychotic symptom rating scales (SAPS, SANS, BPRS, HAM-D and social adaptation scale) were analysed by analysis of variance, which indicated that bromperidol decanoate was effective on almost all parameters. Adverse reactions were reported for 14.3% of the patients, indicating that the drug was very well tolerated; only three patients complained of a total of seven adverse events. In conclusion, bromperidol decanoate was effective in the treatment of residual schizophrenia, with significant differences between before and after treatment ratings for symptoms. The drug was well tolerated, only one patient dropping out on account of adverse reactions.

Original languageItalian
Pages (from-to)39-44
Number of pages6
JournalMinerva Psichiatrica
Volume37
Issue number1
Publication statusPublished - 1996

Fingerprint

Schizophrenia
Pharmaceutical Preparations
Analysis of Variance
Outpatients
Therapeutics
Safety
bromperidol decanoate

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Smeraldi, E., Cocconcelli, C., Canova, L., Faravelli, C., Marchetti, F. P., Mariani, G., & Rapisarda, V. (1996). Bromperidolo decanoato del disturbo schizofrenico in fase residua. Minerva Psichiatrica, 37(1), 39-44.

Bromperidolo decanoato del disturbo schizofrenico in fase residua. / Smeraldi, E.; Cocconcelli, C.; Canova, L.; Faravelli, C.; Marchetti, F. P.; Mariani, G.; Rapisarda, V.

In: Minerva Psichiatrica, Vol. 37, No. 1, 1996, p. 39-44.

Research output: Contribution to journalArticle

Smeraldi, E, Cocconcelli, C, Canova, L, Faravelli, C, Marchetti, FP, Mariani, G & Rapisarda, V 1996, 'Bromperidolo decanoato del disturbo schizofrenico in fase residua', Minerva Psichiatrica, vol. 37, no. 1, pp. 39-44.
Smeraldi E, Cocconcelli C, Canova L, Faravelli C, Marchetti FP, Mariani G et al. Bromperidolo decanoato del disturbo schizofrenico in fase residua. Minerva Psichiatrica. 1996;37(1):39-44.
Smeraldi, E. ; Cocconcelli, C. ; Canova, L. ; Faravelli, C. ; Marchetti, F. P. ; Mariani, G. ; Rapisarda, V. / Bromperidolo decanoato del disturbo schizofrenico in fase residua. In: Minerva Psichiatrica. 1996 ; Vol. 37, No. 1. pp. 39-44.
@article{3eb2137345bb4319a5edb666b46b9057,
title = "Bromperidolo decanoato del disturbo schizofrenico in fase residua",
abstract = "We assessed the safety and therapeutic efficacy of bromperidol decanoate in a six-month open trial on 21 patients (13 males and 8 females), mean age 41.3 years, who were no longer in the acute phase and were being treated as outpatients. The recommended initial dosage was 150 mg bromperidol (one 3 ml ampoule), and this did not in fact have to be increased during the trial. The scores for psychotic symptom rating scales (SAPS, SANS, BPRS, HAM-D and social adaptation scale) were analysed by analysis of variance, which indicated that bromperidol decanoate was effective on almost all parameters. Adverse reactions were reported for 14.3{\%} of the patients, indicating that the drug was very well tolerated; only three patients complained of a total of seven adverse events. In conclusion, bromperidol decanoate was effective in the treatment of residual schizophrenia, with significant differences between before and after treatment ratings for symptoms. The drug was well tolerated, only one patient dropping out on account of adverse reactions.",
keywords = "bromperidol decanoate, residual phase, schizophrenia",
author = "E. Smeraldi and C. Cocconcelli and L. Canova and C. Faravelli and Marchetti, {F. P.} and G. Mariani and V. Rapisarda",
year = "1996",
language = "Italian",
volume = "37",
pages = "39--44",
journal = "Minerva Psichiatrica e Psicologica",
issn = "0391-1772",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Bromperidolo decanoato del disturbo schizofrenico in fase residua

AU - Smeraldi, E.

AU - Cocconcelli, C.

AU - Canova, L.

AU - Faravelli, C.

AU - Marchetti, F. P.

AU - Mariani, G.

AU - Rapisarda, V.

PY - 1996

Y1 - 1996

N2 - We assessed the safety and therapeutic efficacy of bromperidol decanoate in a six-month open trial on 21 patients (13 males and 8 females), mean age 41.3 years, who were no longer in the acute phase and were being treated as outpatients. The recommended initial dosage was 150 mg bromperidol (one 3 ml ampoule), and this did not in fact have to be increased during the trial. The scores for psychotic symptom rating scales (SAPS, SANS, BPRS, HAM-D and social adaptation scale) were analysed by analysis of variance, which indicated that bromperidol decanoate was effective on almost all parameters. Adverse reactions were reported for 14.3% of the patients, indicating that the drug was very well tolerated; only three patients complained of a total of seven adverse events. In conclusion, bromperidol decanoate was effective in the treatment of residual schizophrenia, with significant differences between before and after treatment ratings for symptoms. The drug was well tolerated, only one patient dropping out on account of adverse reactions.

AB - We assessed the safety and therapeutic efficacy of bromperidol decanoate in a six-month open trial on 21 patients (13 males and 8 females), mean age 41.3 years, who were no longer in the acute phase and were being treated as outpatients. The recommended initial dosage was 150 mg bromperidol (one 3 ml ampoule), and this did not in fact have to be increased during the trial. The scores for psychotic symptom rating scales (SAPS, SANS, BPRS, HAM-D and social adaptation scale) were analysed by analysis of variance, which indicated that bromperidol decanoate was effective on almost all parameters. Adverse reactions were reported for 14.3% of the patients, indicating that the drug was very well tolerated; only three patients complained of a total of seven adverse events. In conclusion, bromperidol decanoate was effective in the treatment of residual schizophrenia, with significant differences between before and after treatment ratings for symptoms. The drug was well tolerated, only one patient dropping out on account of adverse reactions.

KW - bromperidol decanoate

KW - residual phase

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0029662070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029662070&partnerID=8YFLogxK

M3 - Articolo

VL - 37

SP - 39

EP - 44

JO - Minerva Psichiatrica e Psicologica

JF - Minerva Psichiatrica e Psicologica

SN - 0391-1772

IS - 1

ER -